Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ngm Biopharmaceuticals Inc (NQ: NGM )

0.7504 -0.0446 (-5.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 155,270
Open 0.7900
Bid (Size) 0.7504 (1)
Ask (Size) 0.7545 (24)
Prev. Close 0.7950
Today's Range 0.7315 - 0.7987
52wk Range 0.6002 - 5.820
Shares Outstanding 78,049,340
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-84.40%
-84.40%
1 Month
-10.71%
-10.71%
3 Month
-58.54%
-58.54%
6 Month
-77.99%
-77.99%
1 Year
-86.60%
-86.60%

More News

Read More
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Bio to Participate in Upcoming Investor Conferences
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Biopharmaceuticals's Return On Capital Employed Insights
Via Benzinga
$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Why InMode Shares Are Trading Lower By 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
NGM Bio to Participate in Upcoming Investor Conferences
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Clinical Setbacks Prompt NGM Bio Lay Off One Third Of Its Staff, Founder Leaves
Via Benzinga
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
From NGM Biopharmaceuticals, Inc.
Via GlobeNewswire
Insiders Buying Charter Communications And 2 Other Stocks
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.